Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rocatinlimab in Adult Subjects With Prurigo Nodularis
NCT06527404Phase 3Terminated
- Sponsor
- Amgen
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 30
01
Overview
A Phase 3 trial of rocatinlimab in prurigo nodularis (PN), sponsored by Amgen. Started Jul 2024; status: terminated.
02
Drugs
rocatinlimab
03
Conditions
prurigo nodularis (PN)
Beyond the preview
Go deeper on NCT06527404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06527404.